What is quviviq?
Quviviq (daridorexant) is a prescription medication approved for the treatment of insomnia [1]. It is a dual orexin receptor antagonist, meaning it works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness [2]. By reducing the stimulation of wakefulness pathways in the brain, Quviviq helps individuals fall asleep and stay asleep [1].
When can generic versions of quviviq be available?
The availability of generic versions of Quviviq depends on the expiration of its patents and any associated exclusivities [3]. Patent expiration dates can be found through resources like DrugPatentWatch.com [4].
What are the key patents for quviviq?
The primary patents protecting Quviviq are typically related to the compound itself, its methods of use, and its manufacturing processes [3]. Information on specific patent numbers and their expiration timelines is maintained by patent offices and databases, which can be accessed through services that track pharmaceutical patents [4].
How does patent exclusivity work for drugs like quviviq?
Following patent expiration, other regulatory exclusivities may apply, which can further delay the entry of generic competitors [3]. These can include pediatric exclusivity or new chemical entity exclusivities. The interplay between these patents and exclusivities determines the earliest possible date for generic approval [4].
Who makes quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [1].
How does quviviq compare to other insomnia treatments?
Quviviq's mechanism of action, targeting the orexin system, differentiates it from other insomnia medications that may act on GABA receptors or melatonin pathways [2]. This distinct approach may offer a different benefit-risk profile for patients [1]. For instance, some older insomnia drugs can lead to next-day grogginess, a side effect that Quviviq aims to minimize due to its selective action [2].
What are the potential risks and side effects of quviviq?
Common side effects associated with Quviviq include headache, fatigue, and nausea [1]. Like other sleep medications, there is a risk of sleep paralysis and hallucinations, particularly if taken shortly before waking or if experiencing disturbed sleep [1]. It is also associated with a warning about potential suicidal thoughts and behaviors [1].
How is quviviq prescribed and dosed?
Quviviq is typically prescribed as a tablet taken once daily at bedtime [1]. The recommended starting dose is 25 mg, with the possibility of increasing to 50 mg if needed [1]. Dosage adjustments may be necessary for individuals with moderate liver impairment [1].
What clinical data supports quviviq's effectiveness?
Clinical trials for Quviviq have demonstrated statistically significant improvements in sleep onset latency and wake after sleep onset compared to placebo [1]. These studies form the basis for its approval by regulatory agencies [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216318s000lbl.pdf
[2] https://www.drugpatentwatch.com/blog/2023/01/11/new-drug-approvals-in-2023/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/